Immune infiltration in invasive lobular breast cancer

114Citations
Citations of this article
134Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Invasive lobular breast cancer (ILC) is the second most common histological subtype of breast cancer after invasive ductal cancer (IDC). Here, we aimed at evaluating the prevalence, levels, and composition of tumor-infiltrating lymphocytes (TILs) and their association with clinico-pathological and outcome variables in ILC, and to compare them with IDC. Methods: We considered two patient series with TIL data: a multicentric retrospective series (n=614) and the BIG 02-98 study (n=149 ILC and 807 IDC). We compared immune subsets identified by immuno-histochemistry in the ILC (n=159) and IDC (n=468) patients from the Nottinghamseries, as well as the CIBERSORT immune profiling of the ILC (n=98) and IDC (n=388) METABRIC and The Cancer Genome Atlas patients. All ILC/IDC comparisons were done in estrogen receptor (ER)-positive/ human epidermal growth factor receptor 2 (HER2)-negative tumors. All statistical tests were two-sided. Results: TIL levels were statistically significantly lower in ILC compared with IDC (fold-change = 0.79, 95% confidence interval = 0.70 to 0.88, P

Cite

CITATION STYLE

APA

Desmedt, C., Salgado, R., Fornili, M., Pruneri, G., Van Den Eynden, G., Zoppoli, G., … Sotiriou, C. (2018). Immune infiltration in invasive lobular breast cancer. Journal of the National Cancer Institute, 110(7), 768–776. https://doi.org/10.1093/jnci/djx268

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free